JP2023520506A5 - - Google Patents

Info

Publication number
JP2023520506A5
JP2023520506A5 JP2022560168A JP2022560168A JP2023520506A5 JP 2023520506 A5 JP2023520506 A5 JP 2023520506A5 JP 2022560168 A JP2022560168 A JP 2022560168A JP 2022560168 A JP2022560168 A JP 2022560168A JP 2023520506 A5 JP2023520506 A5 JP 2023520506A5
Authority
JP
Japan
Application number
JP2022560168A
Other languages
Japanese (ja)
Other versions
JPWO2021202772A5 (https=
JP2023520506A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/025222 external-priority patent/WO2021202772A1/en
Publication of JP2023520506A publication Critical patent/JP2023520506A/ja
Publication of JPWO2021202772A5 publication Critical patent/JPWO2021202772A5/ja
Publication of JP2023520506A5 publication Critical patent/JP2023520506A5/ja
Pending legal-status Critical Current

Links

JP2022560168A 2020-04-01 2021-03-31 Sars-cov-2に対する多層rnaナノ粒子ワクチン Pending JP2023520506A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063003766P 2020-04-01 2020-04-01
US63/003,766 2020-04-01
US202063022999P 2020-05-11 2020-05-11
US63/022,999 2020-05-11
US202063128600P 2020-12-21 2020-12-21
US63/128,600 2020-12-21
PCT/US2021/025222 WO2021202772A1 (en) 2020-04-01 2021-03-31 Multilamellar rna nanoparticle vaccine against sars-cov-2

Publications (3)

Publication Number Publication Date
JP2023520506A JP2023520506A (ja) 2023-05-17
JPWO2021202772A5 JPWO2021202772A5 (https=) 2024-03-22
JP2023520506A5 true JP2023520506A5 (https=) 2024-03-22

Family

ID=75625672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560168A Pending JP2023520506A (ja) 2020-04-01 2021-03-31 Sars-cov-2に対する多層rnaナノ粒子ワクチン

Country Status (6)

Country Link
US (1) US20230226169A1 (https=)
EP (1) EP4126030A1 (https=)
JP (1) JP2023520506A (https=)
AU (1) AU2021247163A1 (https=)
CA (1) CA3174187A1 (https=)
WO (1) WO2021202772A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3999034A4 (en) * 2019-07-19 2023-08-23 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticles
EP3901261A1 (en) 2020-04-22 2021-10-27 BioNTech RNA Pharmaceuticals GmbH Coronavirus vaccine
EP4179328A2 (en) * 2020-07-10 2023-05-17 Covid Diagnostics Ltd. Compositions, methods, and systems for detecting immune response
US20220042117A1 (en) * 2020-08-06 2022-02-10 Roche Molecular Systems, Inc. COMPOSITIONS AND METHODS FOR THE SIMULTANEOUS DETECTION OF INFLUENZA A, INFLUENZA B, AND SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
US20240024466A1 (en) * 2020-12-07 2024-01-25 Trustees Of Tufts College Lipidoid compositions and methods of use thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
WO2024010686A2 (en) * 2022-06-20 2024-01-11 The Trustees Of Columbia University In The City Of New York Vaccine tissue assays
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
WO2025089649A1 (ko) * 2023-10-26 2025-05-01 주식회사 차백신연구소 양이온성 리포좀을 포함하는 핵산 전달용 조성물 및 그의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
MX342785B (es) 2009-06-10 2016-10-12 Alnylam Pharmaceuticals Inc Formulacion mejorada de lipido.
US8802863B2 (en) 2010-05-24 2014-08-12 Sirna Therapeutics, Inc. Amino alcohol cationic lipids for oligonucleotide delivery
US8748667B2 (en) 2010-06-04 2014-06-10 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US11058762B2 (en) * 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
US10245229B2 (en) * 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
CN107073028A (zh) * 2013-12-13 2017-08-18 南洋理工大学 多层纳米颗粒及其制作方法和使用方法
CN111630173A (zh) * 2017-10-19 2020-09-04 库瑞瓦格股份公司 新型人工核酸分子
US10979132B2 (en) * 2018-08-10 2021-04-13 Qualcomm Incorporated Organization of inter-relay discovery reference signals
EP3999034A4 (en) * 2019-07-19 2023-08-23 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticles
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
JP2023552555A5 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)